Jaume Capdevila

Home Tag

Dr. Jaume Capdevila

ESMO Congress 2022: VHIO co-led studies point to a potential new therapeutic strategy and treatment sequence for advanced neuroendocrine tumors

Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity…

Dr. Jaume Capdevila

ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

Selected as an Oral Presentation during the American Society of Clinical Oncology (ASCO) 2021 Virtual Annual Meeting, 04 – 08…